EyePoint, Inc. Common Stock (EYPT) is a publicly traded Healthcare sector company. As of May 21, 2026, EYPT trades at $12.54 with a market cap of $980.94M and a P/E ratio of -3.95. EYPT moved +5.92% today. Year to date, EYPT is -28.28%; over the trailing twelve months it is +101.29%. Its 52-week range spans $3.91 to $19.11. Analyst consensus is strong buy with an average price target of $36.40. Rallies surfaces EYPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
EyePoint’s DURAVYU Phase 3 Trials Secure Third DSMC Review with 35% Third Dose: The Data Safety Monitoring Committee issued its third review recommending LUGANO and LUCIA Phase 3 wet AMD trials of DURAVYU continue without modification, with enrollment exceeding 900 and 35% of patients dosing a third time by Week 56. Topline LUGANO data are on track for mid-2026 after favorable safety findings.
| Metric | Value |
|---|---|
| Price | $12.54 |
| Market Cap | $980.94M |
| P/E Ratio | -3.95 |
| EPS | $-3.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.11 |
| 52-Week Low | $3.91 |
| Volume | 7.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $31.37M |
| Net Income | $-231.96M |
| Gross Margin | 0.00% |
10 analysts cover EYPT: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.40.